Enzyme

Allosteric Inhibition: This process occurs when inhibitor molecules bind to an enzyme at a location other than the active site.
Conformational Change: The binding of the inhibitor at this specific location induces a change in the enzyme's physical shape, known as a conformational change.
Reduced Affinity: As a result of the conformational change, the enzyme's affinity for its substrate is reduced.
Inhibitor Impact: According to Figure $6.18$ , allosteric inhibitors modify the enzyme's active site such that binding of the substrate is either significantly reduced or entirely prevented.

Multi-Polypeptide Composition: Most enzymes that undergo allosteric regulation are composed of more than one polypeptide chain.
Protein Subunits: This structural configuration means these enzymes possess more than one protein subunit.
Global Effect on Active Sites: When a single allosteric inhibitor binds to the enzyme, it causes all active sites on every protein subunit to change slightly.
Binding Efficiency: Following the binding of an inhibitor, all active sites bind their substrates with decreased efficiency.

Allosteric Activators: Beyond inhibitors, enzymes can also be controlled by activators.
Non-Active Site Binding: Like inhibitors, allosteric activators bind to specific locations on an enzyme that are located away from the active site.
Positive Conformational Change: This binding induces a conformational change that has the opposite effect of inhibition.
Increased Affinity: The primary result of an activator's binding is an increase in the affinity of the enzyme’s active site (or multiple sites) for its substrate (or multiple substrates).
Modification Summary: According to Figure $6.18$ , allosteric activators modify the active site specifically to increase the substrate's affinity.

Role of Enzymes in Metabolism: Enzymes are identified as the key components of metabolic pathways.
Foundation of Drug Design: A fundamental principle behind the development of pharmaceutical drugs currently on the market is the detailed understanding of enzyme function and regulation.
Collaborative Scientific Effort: Biologists working in drug discovery typically collaborate with other scientists, most commonly chemists, to design effective drug compounds.
Contextual Illustration: Figure $6.19$ provides a visual context for the development of pharmaceutical drugs.

Classification: Statins represent a specific class of pharmaceutical drugs developed to reduce cholesterol levels.
Inhibition Mechanism: These compounds function as inhibitors of the enzyme $HMG-CoA \text{ reductase}$ .
Biological Function of $HMG-CoA \text{ reductase}$ : This specific enzyme is responsible for the synthesis of cholesterol from lipids within the human body.
Pharmacological Effect: By inhibiting $HMG-CoA \text{ reductase}$ , statin drugs effectively reduce the total amount of cholesterol synthesized by the body.

Product Branding: Acetaminophen is a widely used drug popularly marketed under the brand name Tylenol.
Enzymatic Target: Acetaminophen serves as an inhibitor of the enzyme known as cyclooxygenase.